Roivant Sciences Ltd.
Roivant Sciences Ltd. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in London. In its latest annual figures on file, for the fiscal year ended 2026-03-31, it reported revenue of $8 million and a loss of $398 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.2 out of ten, 9 of 9 metrics filed: past 5.9 out of ten, present 6.5 out of ten, future 3.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 3.6 out of ten. -19.1% a year over 6 filed years; profitable in 1 of 6. 36th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 7.4 out of ten. Share count shrank 0.9% a year. 33% of cash flow returned. Insiders: 122 sales, 0 purchases. 74th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 9.0 out of ten. ROE -6%: lost 6¢ per shareholder dollar. Leverage 7%: owes 7¢ per asset dollar. 90th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 2.4 out of ten. bottom 24% of 314 in its family; net margin -3629.2%. 24th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 5.7 out of ten. top 43% of 315 in its family for leadership; chief executive since 2021. 57th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.9 out of ten. bottom 49% of 272 in its family for room to expand. 49th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 3.9 out of ten. bottom 39% of 307 in its family for growth drivers. 39th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 1.0 out of ten. bottom 10% of 234 in its family for expectations against reality. 10th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-05-20 for the period ended 2026-03-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-10-05. Filings on record since 2015. Read from EDGAR 2026-10-12.
Who runs it
Gline, Matthew (CEO); Venker, Eric (President & Immunovant CEO); Torti, Frank (President and Vant Chair); Sukhatme, Mayukh (President & CIO); Pulik, Richard (CFO); Humes, Jennifer (Chief Accounting Officer); Epperly, Melissa B, (director); Roivant, Sciences Ltd. (director); Fitzgerald, Meghan (director); Gold, Daniel Allen (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-05.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.